LADX Stock Overview
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer.
LadRx Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.18|
|52 Week High||US$0.69|
|52 Week Low||US$0.052|
|1 Month Change||9.39%|
|3 Month Change||125.63%|
|1 Year Change||-69.91%|
|3 Year Change||-37.76%|
|5 Year Change||-91.41%|
|Change since IPO||-99.97%|
Recent News & Updates
|LADX||US Biotechs||US Market|
Return vs Industry: LADX underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: LADX underperformed the US Market which returned -18.5% over the past year.
|LADX Average Weekly Movement||23.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: LADX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: LADX's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company’s advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022.
LadRx Corporation Fundamentals Summary
|LADX fundamental statistics|
Is LADX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LADX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.29|
|Net Profit Margin||0.00%|
How did LADX perform over the long term?See historical performance and comparison